Eisenberger Andrew, Whelan R Lawrence, Neugut Alfred I
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Int J Colorectal Dis. 2008 Jun;23(6):559-68. doi: 10.1007/s00384-008-0456-6. Epub 2008 Mar 11.
Patients with metastatic colorectal cancer have a limited life expectancy and are at risk for life-threatening tumor-related obstruction, perforation, and hemorrhage. Though surgical resection is performed frequently in this setting, its true benefit is not well-established.
We reviewed the medical literature from 1996-2006 using the search terms metastatic colorectal cancer and primary resection to find studies that evaluated the management of primary tumors in metastatic colorectal cancer. All search results were included in our analysis and were assessed on the basis of methodologic quality.
RESULTS/FINDINGS: Twelve relevant studies were identified; ten were single-institution retrospective reviews and two were population-based studies using National Cancer Institute's Surveillance, Epidemiology, and End-Results database. No prospective or randomized studies were identified. Approximately 70% of patients diagnosed with metastatic colorectal cancer in the USA undergo primary tumor resection; only a minority have this done for tumor-related symptoms or as part of potentially curative resection. The postoperative mortality ranged from 9.0-11.2% in large cancer registries but was often lower in major cancer centers. Resection of asymptomatic primary tumors was frequently associated with prolonged survival but was not found to reduce significantly the incidence of life-threatening tumor-related complications.
INTERPRETATION/CONCLUSION: Retrospective data suggest that non-curative resection of asymptomatic colorectal primary tumors may prolong survival; however, selection bias and unaccounted clinical factors may explain this observation. Prospective, randomized surgical trials are needed to test the role of primary tumor resection in this setting, especially because of its current widespread use, and its associated cost, morbidity, and high postoperative mortality.
转移性结直肠癌患者预期寿命有限,且有发生危及生命的肿瘤相关梗阻、穿孔及出血的风险。尽管在此情况下常进行手术切除,但其真正益处尚未明确确立。
我们使用搜索词“转移性结直肠癌”和“原发灶切除”检索了1996年至2006年的医学文献,以查找评估转移性结直肠癌原发肿瘤治疗的研究。所有搜索结果均纳入我们的分析,并根据方法学质量进行评估。
结果/发现:共识别出12项相关研究;10项为单机构回顾性综述,2项为基于美国国立癌症研究所监测、流行病学和最终结果数据库的人群研究。未识别出前瞻性或随机研究。在美国,约70%被诊断为转移性结直肠癌的患者接受原发肿瘤切除;只有少数患者是因肿瘤相关症状或作为潜在根治性切除的一部分而进行手术。在大型癌症登记处,术后死亡率为9.0%至11.2%,但在主要癌症中心通常较低。无症状原发肿瘤的切除常与生存期延长相关,但未发现能显著降低危及生命的肿瘤相关并发症的发生率。
解读/结论:回顾性数据表明,无症状结直肠癌原发肿瘤的非根治性切除可能延长生存期;然而,选择偏倚和未考虑的临床因素可能解释这一观察结果。需要进行前瞻性、随机手术试验来检验原发肿瘤切除在此情况下的作用,特别是鉴于其目前的广泛应用及其相关的成本、发病率和高术后死亡率。